• 1
    Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerging Infect Dis 2006; 12:4854.
  • 2
    Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59:115.
  • 3
    O’Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000; 81:26892696.
  • 4
    Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997; 186:20632068.
  • 5
    Epstein SL, Kong W-P, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23:54045410.
  • 6
    Sambhara S, Kurichh A, Miranda R et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001; 211:143153.
  • 7
    Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001; 75:51415150.
  • 8
    Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 1977; 145:557568.
  • 9
    Fu T-M, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: cytotoxic T lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997; 71:27152721.
  • 10
    Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998; 72:86828689.
  • 11
    Sterkers G, Michon J, Henin Y, Gomard E, Hannoun C, Levy JP. Fine specificity analysis of human influenza-specific cloned cell lines. Cell Immunol 1985; 94:394405.
  • 12
    Gioia C, Castilletti C, Tempestilli M et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerging Infect Dis 2008; 14:121128.
  • 13
    Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162:75787583.
  • 14
    Seo SH, Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001; 75:25162525.
  • 15
    Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159167.
  • 16
    Lipatov AS, Hoffmann E, Salomon R, Yen H-L, Webster RG. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006; 194:10401043.
  • 17
    Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerging Infect Dis 2005; 11:201209.
  • 18
    Bui H-H, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. PNAS 2007; 104:246251.
  • 19
    Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. J Exp Med 1986; 164:11141128.
  • 20
    Scherle PA, Gerhard W. Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. PNAS 1988; 85:44464450.
  • 21
    Bresson J-L, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:16571664.
  • 22
    Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised control trial. Lancet 2006; 368:991997.
  • 23
    Stephenson I, Nicholson KG, Gluck R et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:19591966.
  • 24
    Cox JH, Ferrari G, Janetzki S. Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 2006; 38:274282.
  • 25
    Chapman TJ, Castrucci MR, Padrick RC, Bradley LM, Topham DJ. Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection. Virology 2005; 340:296306.
  • 26
    Hu N, D’Souza C, Cheung H, Lang H, Cheuk E, Chamberlain JW. Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+ H2 class I-deficient mice. Vaccine 2005; 23:52315244.
  • 27
    Riberdy JM, Flynn KJ, Stech J, Webster RG, Altman JD, Doherty PC. Protection against a lethal avian influenza A virus in a mammalian system. J Virol 1999; 73:14531459.
  • 28
    Avetisyan G, Ragnavolgyi E, Toth GT, Hassan M, Ljungman P. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36:411415.
  • 29
    Centre for Disease Control (CDC). Concepts and Procedures for laboratory-based influenza surveillance. U.S. Department of Health, Public Health Service, Atlanta, Georgia: 1982.
  • 30
    Tannock GA, Paul JA, Herd R et al. Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J Clin Microbiol 1989; 27:524528.
  • 31
    Booy R, Brown LE, Grohmann GS, MacIntyre CR. Pandemic vaccines: promises and pitfalls. Med J Aust 2006; 185:S62S65.
  • 32
    Mitchell DM, Callard RE. Fine specificity of the in vitro antibody response to influenza virus by human blood lymphocytes. J Immunol 1983; 131:12291233.
  • 33
    Quinnan GV, Ennis FA, Tuazon CU et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980; 30:362369.
  • 34
    Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 1994; 68:34993504.
  • 35
    Sandbulte MR, Jimenez GS, Boon ACM, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:265272.
  • 36
    Murphy BR, Phelan MA, Nelson DL et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981; 13:554560.
  • 37
    Burlington DB, Wright PF, Van Wyke KL, Phelan MA, Mayner RE, Murphy BR. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985; 21:847849.
  • 38
    Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937943.
  • 39
    Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:13431351.
  • 40
    Beare AS, Webster RG. Replication of avian influenza viruses in humans. Arch Virol 1991; 2:3742.
  • 41
    Profeta ML, Palladino G. Serological evidence of human infections with avian influenza viruses. Brief report. Arch Virol 1986; 4:355360.
  • 42
    Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 10:4446.
  • 43
    Quan F-S, Huang C, Compans RW, Kang S-M. Virus-like particle vaccine induces protective immunity against homolous and heterologous strains of influenza virus. J Virol 2007; 81:35143524.
  • 44
    Sasaki S, Jaimes MC, Holmes TH et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2006; 81:215228.
  • 45
    World Health Organisation Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerging Infect Dis 2005; 11:15151521.
  • 46
    Ennis FA, Cruz J, Jameson J, Klein M, Burt M, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259:256261.
  • 47
    Holtz KM, Anderson DK, Cox MMJ. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J 2005; 2:6573.
  • 48
    Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 influenza virus through adenovirus-based immunization. J Virol 2006; 80:19591964.
  • 49
    Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475481.
  • 50
    Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25:29842989.
  • 51
    Kistner O, Howard MK, Spruth M et al. Cell culture (vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:60286036.